dose-finding study of miriplatin arterial injection therapy for advanced hepatocellular carcinoma
Phase 1
- Conditions
- hepatocellularcarcinoma
- Registration Number
- JPRN-UMIN000014961
- Lead Sponsor
- tokushima university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 9
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Patients with a history of hypersensitivity to contrast agent or drug, including Iodine (2) Patients with (thyroid disease particularly severe, severe cardiac disease) complications (3) serious Patients with double cancer activity (4) Patients with intrahepatic shunt (5) Patients with distant metastases (6) Patients with intention of pregnancy, pregnant women, and lactating women (7) Patients with investigator or investigator was found to be inappropriate as a target
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method